Cargando…
Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, but most tumors show resistance. Resistance is connected to a non-T cell inflamed phenotype partially caused by a lack of functional dendritic cells (DCs) that are crucial for T cell priming. Herein, we investigat...
Autores principales: | Wenthe, Jessica, Naseri, Sedigheh, Hellström, Ann-Charlotte, Moreno, Rafael, Ullenhag, Gustav, Alemany, Ramon, Lövgren, Tanja, Eriksson, Emma, Loskog, Angelica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810301/ https://www.ncbi.nlm.nih.gov/pubmed/35141399 http://dx.doi.org/10.1016/j.omto.2022.01.003 |
Ejemplares similares
-
Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
por: Wenthe, Jessica, et al.
Publicado: (2023) -
Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer
por: Eriksson, Emma, et al.
Publicado: (2016) -
Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
por: Wenthe, Jessica, et al.
Publicado: (2021) -
Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
por: Wenthe, Jessica, et al.
Publicado: (2020) -
Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes
por: Labani-Motlagh, Alireza, et al.
Publicado: (2021)